Eplerenone for the treatment of chronic central serous chorioretinopathy: 3-year clinical experience
British Journal of Ophthalmology May 19, 2019
Petkovsek DS, et al. - Via this retrospective chart analysis, researchers assessed 3-year clinical outcomes of patients who received eplerenone for the treatment of chronic central serous chorioretinopathy (CSCR). At eplerenone initiation, baseline best-corrected visual acuity, as well as anatomical measurements associated with the degree of subretinal fluid (SRF), were obtained. At the closest date to 12, 24 and 36 months, follow-up data were gathered. They collected data at 1-year, 2-year, and 3-year follow-up visits, for 100 eyes of 83 patients, 49 eyes, and for 33 eyes, respectively. The observed rate of complete SRF resolution was 31%, 28% and 33%, respectively. In patients treated with eplerenone for chronic CSCR, the occurrence of anatomical improvement was evident primarily within the first year of treatment.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries